Morgan Stanley
PROF

Morgan Stanley’s Profound Medical PROF Stock Holding History

Morgan Stanley’s Portfolio PROF Stock Details PROF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$47K Buy
7,067
+5,138
+266% +$34.5K ﹤0.01% 6537
2026
Q1 		$12.5K Hold
1,929
– – ﹤0.01% 6884
2025
Q4 		$15.2K Hold
1,929
– – ﹤0.01% 6783
2025
Q3 		$9.43K Sell
1,929
-1,805
-48% -$9.21K ﹤0.01% 6917
2025
Q2 		$22K Sell
3,734
-1,500
-29% -$7.93K ﹤0.01% 6623
2025
Q1 		$30.5K Sell
5,234
-2,555
-33% -$17.6K ﹤0.01% 6433
2024
Q4 		$58.5K Buy
7,789
+3,255
+72% +$25K ﹤0.01% 6240
2024
Q3 		$36.1K Hold
4,534
– – ﹤0.01% 6308
2024
Q2 		$38K Hold
4,534
– – ﹤0.01% 6255
2024
Q1 		$38.7K Sell
4,534
-1,977
-30% -$16.5K ﹤0.01% 6306
2023
Q4 		$55.3K Sell
6,511
-1,223
-16% -$11.6K ﹤0.01% 6125
2023
Q3 		$78.9K Buy
7,734
+1,600
+26% +$16.6K ﹤0.01% 5987
2023
Q2 		$79.8K Buy
6,134
+998
+19% +$12.4K ﹤0.01% 6040
2023
Q1 		$47.7K Sell
5,136
-1,439
-22% -$16.6K ﹤0.01% 6307
2022
Q4 		$71.6K Sell
6,575
-647
-9% -$3.53K ﹤0.01% 6129
2022
Q3 		$29K Buy
7,222
+375
+5% +$2.53K ﹤0.01% 6637
2022
Q2 		$50K Sell
6,847
-1,172
-15% -$9.27K ﹤0.01% 6613
2022
Q1 		$72K Sell
8,019
-750
-9% -$7.22K ﹤0.01% 6507
2021
Q4 		$99K Buy
8,769
+828
+10% +$10.3K ﹤0.01% 6442
2021
Q3 		$116K Sell
7,941
-21,143
-73% -$322K ﹤0.01% 6293
2021
Q2 		$476K Sell
29,084
-24,379
-46% -$454K ﹤0.01% 5553
2021
Q1 		$1.08M Buy
53,463
+8,893
+20% +$213K ﹤0.01% 4683
2020
Q4 		$916K Buy
44,570
+4,169
+10% +$76.7K ﹤0.01% 4726
2020
Q3 		$713K Buy
40,401
+28,221
+232% +$448K ﹤0.01% 4441
2020
Q2 		$206K Sell
12,180
-1,008
-8% -$12.7K ﹤0.01% 5063
2020
Q1 		$129K Buy
13,188
+10,128
+331% +$131K ﹤0.01% 5078
2019
Q4 		$33K Buy
+3,060
New +$28.2K ﹤0.01% 5971

Other funds holding PROF

Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
TIM
Timelo Investment Management Aurora, Ontario, Canada $349M AUM 28.06% 1-Year Est. Return
GA
Gagnon Advisors New York $157M AUM 36.77% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
ZCP
Z3 Capital Partners Richmond, Virginia $476M AUM
LBA
Letko, Brosseau & Associates Montreal, Quebec, Canada $6.77B AUM 38.11% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Morgan Stanley's PROF Position: Q2 2026 in Review

Morgan Stanley increased its Profound Medical (PROF) stake by 266% in Q2 2026, buying an estimated $34.5K and bringing the position to 7,067 shares worth $47K. The position accounts for ﹤0.01% of the portfolio, ranked #6537.

Morgan Stanley first reported a position in PROF in Q4 2019 and has held it in 27 quarters since. The position peaked at $1.08M in Q1 2021. 55 funds tracked by Wall St. Rank hold PROF as of Q2 2026.

  • Morgan Stanley held 7,067 shares of Profound Medical worth $47K as of Q2 2026.
  • Morgan Stanley bought 5,138 Profound Medical shares in Q2 2026, an estimated $34.5K.
  • Profound Medical made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #6537 holding.
  • Morgan Stanley first reported a position in Profound Medical in Q4 2019 and has held it in 27 quarters since.
  • Morgan Stanley's Profound Medical position peaked at $1.08M in Q1 2021.
  • 55 funds tracked by Wall St. Rank held Profound Medical as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.